Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 12/2015

01-12-2015 | Original Contributions

Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery

Authors: Shinhiti Morita, Dalísio De Santi Neto, Flávio Hiroshi Ananias Morita, Nina Kimie Morita, Suzana Margareth Ajeje Lobo

Published in: Obesity Surgery | Issue 12/2015

Login to get access

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) associated with obesity comprises pathological changes ranging from steatosis to steatohepatitis; these can evolve to cirrhosis and hepatocellular carcinoma.

Objectives

The objectives of this study are to assess the prevalence of and predictive markers for steatohepatitis in obese patients undergoing bariatric surgery.

Methods

A prospective study of 184 morbidly obese patients undergoing bariatric surgery formed the study cohort. Patients taking potentially hepatotoxic medications and those with viral diseases and a history of excessive alcohol consumption were excluded. Liver biopsies were performed during surgery with a “Trucut” needle. Patients were classified into the following groups according to the histopathological findings: normal, steatosis, mild steatohepatitis, and moderate-severe steatohepatitis. Factors associated with steatohepatitis were evaluated using logistic regression. p values <0.05 were considered significant.

Results

The prevalence of NAFLD was 84 % (steatosis, 22.0 %; mild steatohepatitis, 30.8 %; moderate-severe steatohepatitis, 32.0 %). Independent predictive factors for steatohepatitis were age (odds ratio (OR), 1.05; 95 % confidence interval (CI), 1.01–1.09; p = 0.011), waist circumference (OR, 1.03; 95 % CI, 1.00–1.06; p = 0.021), serum alanine aminotransferase (ALT) levels (OR, 1.04; 95 % CI, 1.01–1.08; p = 0.005), and serum triglyceride levels (OR, 1.01; 95 % CI, 1.00–1.01; p = 0.042). Score values for each predictor were derived from regression coefficients and odds ratio, and a total (risk) score was obtained from the sum of the points to evaluate the probability of having steatohepatitis.

Conclusion

Age, waist circumference, serum ALT levels, and serum triglyceride levels are efficient and non-invasive predictive markers for the diagnosis and management of steatohepatitis in morbidly obese patients.
Literature
1.
Dixon JB, Bhatal PS, Obrien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in severely obese. Gastroenterology. 2001;121(1):91–100.CrossRefPubMed
2.
Festi D, Colecchia A, Sacco T, et al. Hepatic steatosis in obese patients: clinical aspects and prognostic significance. Obes Rev. 2004;5(1):27–42.CrossRefPubMed
3.
Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50(8):1844–50.CrossRefPubMed
4.
Dixon JB, Bhatal PS, Hughes NR, et al. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology. 2004;39(6):1647–54.CrossRefPubMed
5.
6.
7.
Holterman AX, Guzman G, Fantuzzi G, et al. Nonalcoholic fatty liver disease in severely obese adolescent and adult patients. Obesity (Silver Spring). 2013;21(3):591–7. doi:10.​1002/​oby.​20174.CrossRef
8.
9.
10.
Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol. 2006;45(4):600–6.CrossRefPubMed
11.
12.
Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84(5):1513–7.CrossRefPubMed
13.
Capella RF, Capella JF, Mandec H, et al. Vertical banded gastroplasty-gastric bypass: preliminary report. Obes Surg. 1991;1(4):389–95.CrossRefPubMed
14.
Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology. 2003;37(5):1202–19.CrossRefPubMed
15.
Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.CrossRefPubMed
16.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adult (Adult Treatment Panel III). JAMA. 2001;285(19):2486–97.
17.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–21.CrossRefPubMed
18.
19.
20.
Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356–9.CrossRefPubMed
21.
Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37(4):917–23.CrossRefPubMed
22.
Wolf AM, Busch BB, Kuhlmann HW, et al. Histological changes in the liver of morbidly obese patients: correlation with metabolic parameters. Obes Surg. 2005;15(2):228–37.CrossRefPubMed
23.
Penninx BWJH, Nicklas BJ, Newman AB, et al. Metabolic syndrome and physical decline in older persons: results from the Health, Aging and Body Composition Study. J Gerontol A Biol Sci Med. 2009;64A(1):96–102.CrossRef
24.
Souza MRA, Diniz MFFM, Medeiros-Filho MJEM, et al. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol. 2012;49(1):89–96.CrossRefPubMed
25.
Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22(3):222–6.CrossRefPubMed
26.
Feijo SG, Lima JMC, Oliveira MAA, et al. The spectrum of non alcoholic fatty liver disease in morbidly obese patients. Prevalence and associate risk factors. Acta Cir Bras. 2013;28(11):788–93.CrossRefPubMed
27.
Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gama ligand rosiglitazone. Hepatology. 2003;38(4):1008–17.CrossRefPubMed
28.
Brunt E, Janney CG, Di Bisceglie AM, et al. Nonalcoholic Steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94(9):2467–74.CrossRefPubMed
29.
30.
Sobhonslidsuk A, Jongjirasiri S, Thakkinstian A, et al. Visceral fat and insulin resistance as predictors of non-alcoholic steatohepatitis. World J Gastroenterol. 2007;13(26):3614–8.CrossRefPubMed
31.
32.
Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960–7.CrossRefPubMed
33.
34.
Bass NM, Brunt EM, Clark JM, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913–24.PubMedCentralCrossRefPubMed
35.
De K, Berk PD, Hsu JY, et al. Hepatic pathology among patients without known liver disease undergoing bariatric surgery: observations and a perspective from the Longitudinal Assessment of Bariatric Surgery (LABS) Study. Semin Liver Dis. 2014;34(1):98–107. doi:10.​1055/​s-0034-1371083.CrossRef
36.
Cotrim HP, Parise ER, Oliveira CP, et al. Nonalcoholic fatty liver disease in Brazil. Clinical and Histological profile. Ann Hepatol. 2011;10(1):33–7.PubMed
Metadata
Title
Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery
Authors
Shinhiti Morita
Dalísio De Santi Neto
Flávio Hiroshi Ananias Morita
Nina Kimie Morita
Suzana Margareth Ajeje Lobo
Publication date
01-12-2015
Publisher
Springer US
Published in
Obesity Surgery / Issue 12/2015
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-015-1696-5

Other articles of this Issue 12/2015

Obesity Surgery 12/2015 Go to the issue

Original Contributions

Changes in Health-Related Quality of Life After Gastric Bypass in Patients With and Without Obesity-Related Disease

Letter to the Editor

A Comment on “Obesity Surgery and Ramadan: a Prospective Analysis of Nutritional Intake, Hunger and Satiety and Adaptive Behaviours During Fasting”

Original Contributions

Increasing the Value of Healthcare: Improving Mortality While Reducing Cost in Bariatric Surgery

Original Contributions

Outcomes in Patients with Helicobacter pylori Undergoing Laparoscopic Sleeve Gastrectomy

Original Contributions

Outcomes of Laparoscopic Sleeve Gastrectomy and Roux-en-Y Gastric Bypass in Patients Older than 60

Original Contributions

Optimization of Vitamin D Status After Roux-en-Y Gastric Bypass Surgery in Obese Patients Living in Northern Climate